Pathogen-inspired drug delivery to the central nervous system

References

• Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci 1991; 88:4771-5.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2:3-14; PMID:15717053; http://dx.doi.org/10.1602/neurorx.2.1.3
   PubMedGoogle Scholar
• Bencurova E, Mlynarcik P, Bhide M. An insight into the ligand-receptor interactions involved in the translocation of pathogens across blood-brain barrier. FEMS Immunol Med Microbiol 2011; 63:297-318; PMID:22092557; http://dx.doi.org/10.1111/j.1574-695X.2011.00867.x
   PubMed Web of Science ®Google Scholar
• Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol 2008; 6:625-34; PMID:18604221
   PubMed Web of Science ®Google Scholar
• Salinas S, Schiavo G, Kremer EJ. A hitchhiker's guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 2010; 8:645-55; PMID:20706281; http://dx.doi.org/10.1038/nrmicro2395
   PubMed Web of Science ®Google Scholar
• Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 2010; 8:231-41; PMID:20125087; http://dx.doi.org/10.1038/nrmicro2296
   PubMed Web of Science ®Google Scholar
• Moody MF. Geometry of phage head construction. J Mol Biol 1999; 293:401-33; PMID:10529353
   PubMedGoogle Scholar
• Morton VL, Stockley PG, Stonehouse NJ, Ashcroft AE. Insights into virus capsid assembly from non-covalent mass spectrometry. Mass Spectrom Rev 2008; 27:575-95; PMID:18498137; http://dx.doi.org/10.1002/mas.20176
   PubMedGoogle Scholar
• Jolly CL, Sattentau QJ. Attachment factors. Adv Exp Med Biol 2013; 790:1-23; PMID:23884583; http://dx.doi.org/10.1007/978-1-4614-7651-1_1
   PubMed Web of Science ®Google Scholar
• Mateu MG. Assembly, stability and dynamics of virus capsids. Arch Biochem Biophys 2013; 531:65-79; PMID:23142681
   PubMed Web of Science ®Google Scholar
• Dokland T. Freedom and restraint: themes in virus capsid assembly. Structure 2000; 8:R157-62; PMID:10997898; http://dx.doi.org/10.1016/S0969-2126(00)00181-7
   PubMedGoogle Scholar
• Wu E, Nemerow GR. Virus yoga: the role of flexibility in virus host cell recognition. Trends Microbiol 2004; 12:162-9; PMID:15051066; http://dx.doi.org/10.1016/j.tim.2004.02.005
   PubMedGoogle Scholar
• Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007; 81:13149-57; PMID:17804513; http://dx.doi.org/10.1128/JVI.01415-07
   PubMed Web of Science ®Google Scholar
• McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol 2011; 11:318-29; PMID:21508982; http://dx.doi.org/10.1038/nri2971
   PubMed Web of Science ®Google Scholar
• Johnson N, Phillpotts R, Fooks AR. Airborne transmission of lyssaviruses. J Med Microbiol 2006; 55:785-90; PMID:16687600; http://dx.doi.org/10.1099/jmm.0.46370-0
   PubMedGoogle Scholar
• Lafon M. Rabies virus receptors. J Neurovirol 2005; 11:82-7
   PubMed Web of Science ®Google Scholar
• Langevin C, Jaaro H, Bressanelli S, Fainzilber M, Tuffereau C. Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor. J Biol Chem 2002; 277:37655-62; PMID:12163480; http://dx.doi.org/10.1074/jbc.M201374200
   PubMedGoogle Scholar
• Thoulouze MI, Lafage M, Schachner M, Hartmann U, Cremer H, Lafon M. The neural cell adhesion molecule is a receptor for rabies virus. J Virol 1998; 72:7181-90; PMID:9696812
   PubMed Web of Science ®Google Scholar
• Lentz TL. Rabies virus binding to an acetylcholine receptor alpha-subunit peptide. J Mol Recognit 1990; 3:82-8
   PubMedGoogle Scholar
• Superti F, Derer M, Tsiang H. Mechanism of rabies virus entry into CER cells. J Gen Virol 1984; 65(Pt 4):781-9; PMID:6423770; http://dx.doi.org/10.1099/0022-1317-65-4-781
   PubMedGoogle Scholar
• Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol 2009; 15:111-22; PMID:19306229; http://dx.doi.org/10.1080/13550280902769764
   PubMed Web of Science ®Google Scholar
• Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011; 1399:96-115; PMID:21641584; http://dx.doi.org/10.1016/j.brainres.2011.05.015
   PubMed Web of Science ®Google Scholar
• King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neurotoxicity. Microbes Infect 2006; 8:1347-57; PMID:16697675; http://dx.doi.org/10.1016/j.micinf.2005.11.014
   PubMed Web of Science ®Google Scholar
• Cohen SS, Li C, Ding L, Cao Y, Pardee AB, Shevach EM, Cohen DI. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci U S A 1999; 96:10842-7; PMID:10485913; http://dx.doi.org/10.1073/pnas.96.19.10842
   PubMed Web of Science ®Google Scholar
• Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005; 193:218-27; PMID:15817280; http://dx.doi.org/10.1016/j.expneurol.2004.11.019
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhang Q, Chen H, Yuan W, Kuai R, Xie F, Zhang L, Wang X, Zhang Z, Liu J, et al. Comparison of four different peptides to enhance accumulation of liposomes into the brain. J Drug Target 2012; 20:235-45; PMID:22188312; http://dx.doi.org/10.3109/1061186X.2011.639022
   PubMed Web of Science ®Google Scholar
• Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002; 5:141-51; PMID:12831055; http://dx.doi.org/10.1023/A:1023892223074
   PubMedGoogle Scholar
• Margolin W. Sculpting the bacterial cell. Curr Biol 2009; 19:R812-22; PMID:19906583
   PubMedGoogle Scholar
• Typas A, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat Rev Microbiol 2012; 10:123-36;
   Web of Science ®Google Scholar
• Huang SH, Jong AY. Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cell Microbiol 2001; 3:277-87; PMID:11298651; http://dx.doi.org/10.1046/j.1462-5822.2001.00116.x
   PubMed Web of Science ®Google Scholar
• Toivonen JM, Olivan S, Osta R. Tetanus toxin C-fragment: the courier and the cure? Toxins 2010; 2:2622-44; PMID:22069568; http://dx.doi.org/10.3390/toxins2112622
   PubMed Web of Science ®Google Scholar
• Rossetto O, Scorzeto M, Megighian A, Montecucco C. Tetanus neurotoxin. Toxicon: Off J Int Soc Toxinol 2013; 66:59-63; PMID:23419592; http://dx.doi.org/10.1016/j.toxicon.2012.12.027
   PubMedGoogle Scholar
• Matsuda M, Lei DL, Sugimoto N, Ozutsumi K, Okabe T. Isolation, purification, and characterization of fragment B, the NH2-terminal half of the heavy chain of tetanus toxin. Infect Immun 1989; 57:3588-93; PMID:2478476
   PubMed Web of Science ®Google Scholar
• Boquet P, Duflot E. Tetanus toxin fragment forms channels in lipid vesicles at low pH. Proc Natl Acad Sci U S A 1982; 79:7614-8; PMID:6296842; http://dx.doi.org/10.1073/pnas.79.24.7614
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Adult vaccination coverage–United States, 2010. MMWR Morbidity and mortality weekly report 2012; 61:66-72.
   Google Scholar
• Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnaga A, Kato K, Kaji R, Kozaki S. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 2013; 591:1031-43; PMID:23109108; http://dx.doi.org/10.1113/jphysiol.2012.242131
   PubMedGoogle Scholar
• Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci: Off J Soc Neurosci 2008; 28:3689-96; PMID:18385327; http://dx.doi.org/10.1523/JNEUROSCI.0375-08.2008
   PubMed Web of Science ®Google Scholar
• Pulzova L, Bhide M. Outer surface proteins of Borrelia: peerless immune evasion tools. Curr Protein Pept Sci 2014; 15:75-88; PMID:24555888; http://dx.doi.org/10.2174/1389203715666140221124213
   PubMedGoogle Scholar
• Leong JM, Wang H, Magoun L, Field JA, Morrissey PE, Robbins D, Tatro JB, Coburn J, Parveen N. Different classes of proteoglycans contribute to the attachment of Borrelia burgdorferi to cultured endothelial and brain cells. Infect Immun 1998; 66:994-9; PMID:9488387
   PubMed Web of Science ®Google Scholar
• Moriarty TJ, Shi M, Lin YP, Ebady R, Zhou H, Odisho T, Hardy PO, Salman-Dilgimen A, Wu J, Weening EH, et al. Vascular binding of a pathogen under shear force through mechanistically distinct sequential interactions with host macromolecules. Mol Microbiol 2012; 86:1116-31; PMID:23095033; http://dx.doi.org/10.1111/mmi.12045
   PubMedGoogle Scholar
• Pulzova L, Kovac A, Mucha R, Mlynarcik P, Bencurova E, Madar M, Novak M, Bhide M. OspA-CD40 dyad: ligand-receptor interaction in the translocation of neuroinvasive Borrelia across the blood-brain barrier. Sci Rep 2011; 1:86; PMID:22355605; http://dx.doi.org/10.1038/srep00086
   PubMed Web of Science ®Google Scholar
• Reddy MA, Prasadarao NV, Wass CA, Kim KS. Phosphatidylinositol 3-kinase activation and interaction with focal adhesion kinase in Escherichia coli K1 invasion of human brain microvascular endothelial cells. J Biol Chem 2000; 275:36769-74; PMID:10973983; http://dx.doi.org/10.1074/jbc.M007382200
   PubMedGoogle Scholar
• Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K. Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature 1997; 387:725-9; PMID:9192900; http://dx.doi.org/10.1038/42735
   PubMed Web of Science ®Google Scholar
• Khan NA, Shin S, Chung JW, Kim KJ, Elliott S, Wang Y, Kim KS. Outer membrane protein A and cytotoxic necrotizing factor-1 use diverse signaling mechanisms for Escherichia coli K1 invasion of human brain microvascular endothelial cells. Microb Pathogenesis 2003; 35:35-42; PMID:12860457; http://dx.doi.org/10.1016/S0882-4010(03)00090-1
   PubMedGoogle Scholar
• Abouseada NM, Assafi MS, Mahdavi J, Oldfield NJ, Wheldon LM, Wooldridge KG, Ala'Aldeen DA. Mapping the laminin receptor binding domains of Neisseria meningitidis PorA and Haemophilus influenzae OmpP2. PloS One 2012; 7:e46233; PMID:23049988
   PubMedGoogle Scholar
• Kim KJ, Chung JW, Kim KS. 67-kDa laminin receptor promotes internalization of cytotoxic necrotizing factor 1-expressing Escherichia coli K1 into human brain microvascular endothelial cells. J Biol Chem 2005; 280:1360-8; PMID:15516338; http://dx.doi.org/10.1074/jbc.M410176200
   PubMed Web of Science ®Google Scholar
• Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala'Aldeen DA, Tuomanen EI. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Investi 2009; 119:1638-46; PMID:19436113; http://dx.doi.org/10.1172/JCI36759
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3:569-81; PMID:12876559; http://dx.doi.org/10.1038/nri1130
   PubMed Web of Science ®Google Scholar
• Drevets DA, Dillon MJ, Schawang JS, Van Rooijen N, Ehrchen J, Sunderkotter C, Leenen PJ. The Ly-6Chigh monocyte subpopulation transports Listeria monocytogenes into the brain during systemic infection of mice. J Immunol 2004; 172:4418-24; http://dx.doi.org/10.4049/jimmunol.172.7.4418
   PubMed Web of Science ®Google Scholar
• Hertzig T, Weber M, Greiffenberg L, Holthausen BS, Goebel W, Kim KS, Kuhn M. Antibodies present in normal human serum inhibit invasion of human brain microvascular endothelial cells by Listeria monocytogenes. Infect Immun 2003; 71:95-100; PMID:12496153; http://dx.doi.org/10.1128/IAI.71.1.95-100.2003
   PubMed Web of Science ®Google Scholar
• Remuzgo-Martinez S, Pilares-Ortega L, Icardo JM, Valdizan EM, Vargas VI, Pazos A, Ramos-Vivas J. Microglial activation and expression of immune-related genes in a rat ex vivo nervous system model after infection with Listeria monocytogenes. Glia 2013; 61:611-22; PMID:23322603; http://dx.doi.org/10.1002/glia.22459
   PubMedGoogle Scholar
• Greiffenberg L, Goebel W, Kim KS, Weiglein I, Bubert A, Engelbrecht F, Stins M, Kuhn M. Interaction of Listeria monocytogenes with human brain microvascular endothelial cells: InlB-dependent invasion, long-term intracellular growth, and spread from macrophages to endothelial cells. Infect Immun 1998; 66:5260-7; PMID:9784531
   PubMed Web of Science ®Google Scholar
• Klint JK, Senff S, Rupasinghe DB, Er SY, Herzig V, Nicholson GM, King GF. Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. Toxicon: Off J Int Soc Toxinol 2012; 60:478-91; PMID:22543187; http://dx.doi.org/10.1016/j.toxicon.2012.04.337
   PubMedGoogle Scholar
• King GF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther 2011; 11:1469-84; PMID:21939428; http://dx.doi.org/10.1517/14712598.2011.621940
   PubMed Web of Science ®Google Scholar
• Norton RS, Pallaghy PK. The cystine knot structure of ion channel toxins and related polypeptides. Toxicon: Off J Int Soc Toxinol 1998; 36:1573-83; PMID:9792173; http://dx.doi.org/10.1016/S0041-0101(98)00149-4
   PubMedGoogle Scholar
• Mouhat S, Jouirou B, Mosbah A, De Waard M, Sabatier JM. Diversity of folds in animal toxins acting on ion channels. Biochem J 2004; 378:717-26; PMID:14674883; http://dx.doi.org/10.1042/BJ20031860
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kim JI, Min HJ, Sato K, Swartz KJ, Shimada I. Solution structure of hanatoxin1, a gating modifier of voltage-dependent K(+) channels: common surface features of gating modifier toxins. J Mol Biol 2000; 297:771-80; PMID:10731427; http://dx.doi.org/10.1006/jmbi.2000.3609
   PubMed Web of Science ®Google Scholar
• Chagot B, Escoubas P, Villegas E, Bernard C, Ferrat G, Corzo G, Lazdunski M, Darbon H. Solution structure of Phrixotoxin 1, a specific peptide inhibitor of Kv4 potassium channels from the venom of the theraphosid spider Phrixotrichus auratus. Protein Sci 2004; 13:1197-208; PMID:15096626; http://dx.doi.org/10.1110/ps.03584304
   PubMed Web of Science ®Google Scholar
• Raposo C, Odorissi PA, Oliveira AL, Aoyama H, Ferreira CV, Verinaud L, Fontana K, Ruela-de-Sousa RR, da Cruz-Hofling MA. Effect of Phoneutria nigriventer venom on the expression of junctional protein and P-gp efflux pump function in the blood-brain barrier. Neurochem Res 2012; 37:1967-81; PMID:22684283; http://dx.doi.org/10.1007/s11064-012-0817-y
   PubMedGoogle Scholar
• de Paula Le Sueur L, Kalapothakis E, da Cruz-Hofling MA. Breakdown of the blood-brain barrier and neuropathological changes induced by Phoneutria nigriventer spider venom. Acta Neuropathol 2003; 105:125-34; PMID:12536223
   PubMed Web of Science ®Google Scholar
• Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006; 27:482-91; PMID:16876883; http://dx.doi.org/10.1016/j.tips.2006.07.004
   PubMed Web of Science ®Google Scholar
• Harvey AL. Snake venom peptides. Handbook of Biologically Active Peptides 2006:355-62.
   Google Scholar
• Kini RM, Doley R. Structure, function and evolution of three-finger toxins: mini proteins with multiple targets. Toxicon: Off J Int Soc Toxinol 2010; 56:855-67; PMID:20670641; http://dx.doi.org/10.1016/j.toxicon.2010.07.010
   PubMedGoogle Scholar
• Kumari S, Borroni V, Chaudhry A, Chanda B, Massol R, Mayor S, Barrantes FJ. Nicotinic acetylcholine receptor is internalized via a Rac-dependent, dynamin-independent endocytic pathway. J Cell Biol 2008; 181:1179-93; PMID:18591431; http://dx.doi.org/10.1083/jcb.200709086
   PubMed Web of Science ®Google Scholar
• Osipov AV, Rucktooa P, Kasheverov IE, Filkin SY, Starkov VG, Andreeva TV, Sixma TK, Bertrand D, Utkin YN, Tsetlin VI. Dimeric alpha-Cobratoxin X-ray Structure: Localization of intermolecular disulfides and possible mode of binding to nicotinic acetylcholine receptors*. J Biol Chem 2012; 287:6725-34; PMID:22223648; http://dx.doi.org/10.1074/jbc.M111.322313
   PubMedGoogle Scholar
• Alama A, Bruzzo C, Cavalieri Z, Forlani A, Utkin Y, Casciano I, Romani M. Inhibition of the nicotinic acetylcholine receptors by cobra venom alpha-neurotoxins: is there a perspective in lung cancer treatment? PloS One 2011; 6:e20695; PMID:21695184
   PubMedGoogle Scholar
• Lesovoy DM, Bocharov EV, Lyukmanova EN, Kosinsky YA, Shulepko MA, Dolgikh DA, Kirpichnikov MP, Efremov RG, Arseniev AS. Specific membrane binding of neurotoxin II can facilitate its delivery to acetylcholine receptor. Biophys J 2009; 97:2089-97; PMID:19804741; http://dx.doi.org/10.1016/j.bpj.2009.07.037
   PubMed Web of Science ®Google Scholar
• Colquhoun D, Unwin N, Shelley C, Hatton C, Sivilotti L. Burger's medicinal chemistry and drug discovery. New York: Wiley-Interscience; 2003.
   Google Scholar
• Redwan el RM. Animal-derived pharmaceutical proteins. J Immunoassay Immunochem 2009; 30:262-90; PMID:19591041; http://dx.doi.org/10.1080/15321810903084400
   PubMedGoogle Scholar
• Essack M, Bajic VB, Archer JA. Conotoxins that confer therapeutic possibilities. Marine drugs 2012; 10:1244-65; PMID:22822370; http://dx.doi.org/10.3390/md10061244
   PubMedGoogle Scholar
• Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev 2012; 64:259-98; PMID:22407615; http://dx.doi.org/10.1124/pr.111.005322
   PubMed Web of Science ®Google Scholar
• Hone AJ, Ruiz M, Scadden M, Christensen S, Gajewiak J, Azam L, McIntosh JM. Positional scanning mutagenesis of alpha-conotoxin PeIA identifies critical residues that confer potency and selectivity for alpha6/alpha3beta2beta3 and alpha3beta2 nicotinic acetylcholine receptors. J Biol Chem 2013; 288:25428-39; PMID:23846688; http://dx.doi.org/10.1074/jbc.M113.482059
   PubMedGoogle Scholar
• National Select Agent Registry. Centers for Disease Control; 2013; http://www.selectagents.gov/Select%20Agents%20and%20Toxins%20List.html
   Google Scholar
• Ding J, Chua PJ, Bay BH, Gopalakrishnakone P. Scorpion venoms as a potential source of novel cancer therapeutic compounds. Exp Biol Med (Maywood) 2014; 239(4):387-93.
   Web of Science ®Google Scholar
• Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002; 39:162-73; PMID:12112367; http://dx.doi.org/10.1002/glia.10083
   PubMed Web of Science ®Google Scholar
• Gordon D, Gurevitz M. The selectivity of scorpion alpha-toxins for sodium channel subtypes is determined by subtle variations at the interacting surface. Toxicon: Off J Int Soc Toxinol 2003; 41:125-8; PMID:12565730; http://dx.doi.org/10.1016/S0041-0101(02)00294-5
   PubMedGoogle Scholar
• Zhijian C, Feng L, Yingliang W, Xin M, Wenxin L. Genetic mechanisms of scorpion venom peptide diversification. Toxicon 2006; 47:348-55; PMID:16387337; http://dx.doi.org/10.1016/j.toxicon.2005.11.013
   PubMedGoogle Scholar
• Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29:341-5; PMID:21423189; http://dx.doi.org/10.1038/nbt.1807
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448:39-43; PMID:17572664; http://dx.doi.org/10.1038/nature05901
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998; 58:4871-9; PMID:9809993
   PubMed Web of Science ®Google Scholar
• Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007; 67:6882-8; PMID:17638899; http://dx.doi.org/10.1158/0008-5472.CAN-06-3948
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006; 24:3644-50; PMID:16877732; http://dx.doi.org/10.1200/JCO.2005.05.4569
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Mendonca LS, Serani A, Custodia C, Conceicao M, Simoes S, Moreira JN, Pereira de Almeida L, Pedroso de Lima MC. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids 2013; 2:e100; PMID:23778499
   PubMedGoogle Scholar
• Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 2011; 32:2399-406; PMID:21185076; http://dx.doi.org/10.1016/j.biomaterials.2010.11.079
   PubMed Web of Science ®Google Scholar
• Kievit FM, Veiseh O, Fang C, Bhattarai N, Lee D, Ellenbogen RG, Zhang M. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010; 4:4587-94; PMID:20731441; http://dx.doi.org/10.1021/nn1008512
   PubMed Web of Science ®Google Scholar
• Mok H, Veiseh O, Fang C, Kievit FM, Wang FY, Park JO, Zhang M. pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm 2010; 7:1930-9; PMID:20722417; http://dx.doi.org/10.1021/mp100221h
   PubMed Web of Science ®Google Scholar
• Veiseh O, Kievit FM, Fang C, Mu N, Jana S, Leung MC, Mok H, Ellenbogen RG, Park JO, Zhang M. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 2010; 31:8032-42; PMID:20673683; http://dx.doi.org/10.1016/j.biomaterials.2010.07.016
   PubMed Web of Science ®Google Scholar
• Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 2009; 30:649-57; PMID:18990439; http://dx.doi.org/10.1016/j.biomaterials.2008.10.003
   PubMed Web of Science ®Google Scholar
• Kasai T, Nakamura K, Vaidyanath A, Chen L, Sekhar S, El-Ghlban S, Okada M, Mizutani A, Kudoh T, Murakami H, et al. Chlorotoxin fused to IgG-Fc inhibits glioblastoma cell motility via receptor-mediated endocytosis. J Drug Del 2012; 2012:975763; PMID:23304519; http://dx.doi.org/10.1155/2012/975763
   PubMedGoogle Scholar
• Locatelli E, Naddaka M, Uboldi C, Loudos G, Fragogeorgi E, Molinari V, Pucci A, Tsotakos T, Psimadas D, Ponti J, et al. Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma. Nanomedicine 2014; 9(6):839-49; PMID:24433240
   PubMed Web of Science ®Google Scholar
• Locatelli E, Broggi F, Ponti J, Marmorato P, Franchini F, Lena S, Franchini MC. Lipophilic silver nanoparticles and their polymeric entrapment into targeted-PEG-based micelles for the treatment of glioblastoma. Adv Healthc Mater 2012; 1:342-7; PMID:23184752; http://dx.doi.org/10.1002/adhm.201100047
   PubMedGoogle Scholar
• Xiang Y, Wu Q, Liang L, Wang X, Wang J, Zhang X, Pu X, Zhang Q. Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model. J Drug Target 2012; 20:67-75; PMID:22149216; http://dx.doi.org/10.3109/1061186X.2011.595490
   PubMed Web of Science ®Google Scholar
• Huang R, Han L, Li J, Liu S, Shao K, Kuang Y, Hu X, Wang X, Lei H, Jiang C. Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis. Biomaterials 2011; 32:5177-86; PMID:21531455; http://dx.doi.org/10.1016/j.biomaterials.2011.03.075
   PubMed Web of Science ®Google Scholar
• Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release: Off J Control Release Soc 2011; 152:402-10; PMID:21435361; http://dx.doi.org/10.1016/j.jconrel.2011.03.014
   PubMed Web of Science ®Google Scholar
• Fang C, Veiseh O, Kievit F, Bhattarai N, Wang F, Stephen Z, Li C, Lee D, Ellenbogen RG, Zhang M. Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior. Nanomedicine 2010; 5:1357-69; PMID:21128719; http://dx.doi.org/10.2217/nnm.10.55
   PubMed Web of Science ®Google Scholar
• Lee MJ, Veiseh O, Bhattarai N, Sun C, Hansen SJ, Ditzler S, Knoblaugh S, Lee D, Ellenbogen R, Zhang M, et al. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 2010; 5:e9536; PMID:AMBIGUOUS
   PubMedGoogle Scholar
• Meng XX, Wan JQ, Jing M, Zhao SG, Cai W, Liu EZ. Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents. Acta Pharmacol Sinic 2007; 28:2019-26; PMID:18031618; http://dx.doi.org/10.1111/j.1745-7254.2007.00661.x
   PubMedGoogle Scholar
• Sun C, Du K, Fang C, Bhattarai N, Veiseh O, Kievit F, Stephen Z, Lee D, Ellenbogen RG, Ratner B, et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 2010; 4:2402-10; PMID:20232826; http://dx.doi.org/10.1021/nn100190v
   PubMed Web of Science ®Google Scholar
• Sun C, Fang C, Stephen Z, Veiseh O, Hansen S, Lee D, Ellenbogen RG, Olson J, Zhang M. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine 2008; 3:495-505; PMID:18694312; http://dx.doi.org/10.2217/17435889.3.4.495
   PubMed Web of Science ®Google Scholar
• Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008; 4:372-9; PMID:18232053; http://dx.doi.org/10.1002/smll.200700784
   PubMed Web of Science ®Google Scholar
• Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS, Zhang M. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 2009; 5:256-64; PMID:19089837; http://dx.doi.org/10.1002/smll.200800646
   PubMed Web of Science ®Google Scholar
• Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, Du K, Pullar B, Lee D, Ellenbogen RG, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009; 69:6200-7; PMID:19638572; http://dx.doi.org/10.1158/0008-5472.CAN-09-1157
   PubMed Web of Science ®Google Scholar
• Wan J, Meng X, Liu E, Chen K. Incorporation of magnetite nanoparticle clusters in fluorescent silica nanoparticles for high-performance brain tumor delineation. Nanotechnology 2010; 21:235104; PMID:20472942; http://dx.doi.org/10.1088/0957-4484/21/23/235104
   PubMedGoogle Scholar
• Orndorff RL, Rosenthal SJ. Neurotoxin quantum dot conjugates detect endogenous targets expressed in live cancer cells. Nano Letters 2009; 9:2589-99; PMID:19507837; http://dx.doi.org/10.1021/nl900789e
   PubMed Web of Science ®Google Scholar
• Safdar S, Payne CA, Tu NH, Taite LJ. Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. Biotechnol Bioeng 2013; 110:1211-20; PMID:23125026; http://dx.doi.org/10.1002/bit.24775
   PubMedGoogle Scholar
• Zhan C, Yan Z, Xie C, Lu W. Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. Mol Pharm 2010; 7:1940-7; PMID:20964364; http://dx.doi.org/10.1021/mp100238j
   PubMed Web of Science ®Google Scholar
• Maus L, Dick O, Bading H, Spatz JP, Fiammengo R. Conjugation of peptides to the passivation shell of gold nanoparticles for targeting of cell-surface receptors. ACS Nano 2010; 4:6617-28; PMID:20939520; http://dx.doi.org/10.1021/nn101867w
   PubMed Web of Science ®Google Scholar
• Francis JW, Figueiredo D, vanderSpek JC, Ayala LM, Kim YS, Remington MP, Young PJ, Lorson CL, Ikebe S, Fishman PS, et al. A survival motor neuron:tetanus toxin fragment C fusion protein for the targeted delivery of SMN protein to neurons. Brain Res 2004; 995:84-96; PMID:14644474; http://dx.doi.org/10.1016/j.brainres.2003.09.063
   PubMedGoogle Scholar
• Ciriza J, Moreno-Igoa M, Calvo AC, Yague G, Palacio J, Miana-Mena FJ, Munoz MJ, Zaragoza P, Brulet P, Osta R. A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model. Restor Neurol Neurosci 2008; 26:459-65; PMID:19096133
   PubMed Web of Science ®Google Scholar
• Chian RJ, Li J, Ay I, Celia SA, Kashi BB, Tamrazian E, Matthews JC, Bronson RT, Rossomando A, Pepinsky RB, et al. IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice. Brain Res 2009; 1287:1-19; PMID:19563785; http://dx.doi.org/10.1016/j.brainres.2009.06.066
   PubMed Web of Science ®Google Scholar
• Figueiredo DM, Hallewell RA, Chen LL, Fairweather NF, Dougan G, Savitt JM, Parks DA, Fishman PS. Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport. Exp Neurol 1997; 145:546-54; PMID:9217090; http://dx.doi.org/10.1006/exnr.1997.6490
   PubMed Web of Science ®Google Scholar
• Favretto ME, Wallbrecher R, Schmidt S, van de Putte R, Brock R. Glycosaminoglycans in the cellular uptake of drug delivery vectors - Bystanders or active players? J Control Release: Off J Control Release Soc 2014; 180C:81-90; http://dx.doi.org/10.1016/j.jconrel.2014.02.011
   Web of Science ®Google Scholar
• Ng CP, Goodman TT, Park IK, Pun SH. Bio-mimetic surface engineering of plasmid-loaded nanoparticles for active intracellular trafficking by actin comet-tail motility. Biomaterials 2009; 30:951-8; PMID:19046764; http://dx.doi.org/10.1016/j.biomaterials.2008.10.059
   PubMedGoogle Scholar
• Niu Y, Yu M, Hartono SB, Yang J, Xu H, Zhang H, Zhang J, Zou J, Dexter A, Gu W, et al. Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv Mater 2013; 25:6233-7; PMID:23946251; http://dx.doi.org/10.1002/adma.201302737
   PubMed Web of Science ®Google Scholar
• Srikanth M, Kessler JA. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol 2012; 8:307-18; PMID:22526003; http://dx.doi.org/10.1038/nrneurol.2012.76
   PubMed Web of Science ®Google Scholar
• Schneider-Schaulies J, Meulen V, Schneider-Schaulies S. Measles infection of the central nervous system. J Neurovirol 2003; 9:247-52; PMID:12707855; http://dx.doi.org/10.1080/13550280390193993
   PubMedGoogle Scholar
• Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 2004; 14:5-8.
   PubMed Web of Science ®Google Scholar
• Li Q, Ali MA, Cohen JI. Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell 2006; 127:305-16; PMID:17055432; http://dx.doi.org/10.1016/j.cell.2006.08.046
   PubMedGoogle Scholar
• Chen JJ, Zhu Z, Gershon AA, Gershon MD. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 2004; 119:915-26; PMID:15620351; http://dx.doi.org/10.1016/j.cell.2004.11.007
   PubMed Web of Science ®Google Scholar
• Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D. Mechanisms of HIV-1 neurotropism. Curr HIV Res 2006; 4:267-78; PMID:16842080; http://dx.doi.org/10.2174/157016206777709500
   PubMed Web of Science ®Google Scholar
• Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366-73; PMID:15558055; http://dx.doi.org/10.1038/nm1140
   PubMed Web of Science ®Google Scholar
• Chu JJ, Ng ML. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem 2004; 279:54533-41; PMID:15475343; http://dx.doi.org/10.1074/jbc.M410208200
   PubMed Web of Science ®Google Scholar
• Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006; 344:9-16; PMID:AMBIGUOUS
   PubMed Web of Science ®Google Scholar
• Chung JW, Hong SJ, Kim KJ, Goti D, Stins MF, Shin S, Dawson VL, Dawson TM, Kim KS. 37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake. J Biol Chem 2003; 278:16857-62; PMID:12615923; http://dx.doi.org/10.1074/jbc.M301028200
   PubMed Web of Science ®Google Scholar
• Thepparit C, Smith DR. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol 2004; 78:12647-56; PMID:15507651; http://dx.doi.org/10.1128/JVI.78.22.12647-12656.2004
   PubMed Web of Science ®Google Scholar
• Bogachek MV, Protopopova EV, Loktev VB, Zaitsev BN, Favre M, Sekatskii SK, Dietler G. Immunochemical and single molecule force spectroscopy studies of specific interaction between the laminin binding protein and the West Nile virus surface glycoprotein E domain II. J Mol Recognit 2008; 21:55-62; PMID:18061925; http://dx.doi.org/10.1002/jmr.866
   PubMed Web of Science ®Google Scholar
• Protopopova EV, Sorokin AV, Konovalova SN, Kachko AV, Netesov SV, Loktev VB. Human laminin binding protein as a cell receptor for the tick-borne encephalitis virus. Zbl Bakt 1999; 289:632-8; PMID:10215633
   PubMedGoogle Scholar
• Hurtado A, Tseng JC, Boivin C, Levin B, Yee H, Pampeno C, Meruelo D. Identification of amino acids of Sindbis virus E2 protein involved in targeting tumor metastases in vivo. Mol Ther: J Am Soc Gene Ther 2005; 12:813-23; PMID:16109508; http://dx.doi.org/10.1016/j.ymthe.2005.06.476
   PubMedGoogle Scholar
• Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992; 66:4992-5001; PMID:1385835
   PubMed Web of Science ®Google Scholar
• Thongtan T, Wikan N, Wintachai P, Rattanarungsan C, Srisomsap C, Cheepsunthorn P, Smith DR. Characterization of putative Japanese encephalitis virus receptor molecules on microglial cells. J Med Virol 2012; 84:615-23; PMID:22337301; http://dx.doi.org/10.1002/jmv.23248
   PubMed Web of Science ®Google Scholar
• Zhan C, Yan Z, Xie C, Lu W. Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. Mol Pharm 2010; 7:1940-7; PMID:20964364; http://dx.doi.org/10.1021/mp100238j
   PubMed Web of Science ®Google Scholar
• Marcon F, Leblanc M, Vetter I, Lewis RJ, Escoubas P, Nicholson GM. Pharmacological characterization of alpha-elapitoxin-Al2a from the venom of the Australian pygmy copperhead (Austrelaps labialis): an atypical long-chain alpha-neurotoxin with only weak affinity for alpha7 nicotinic receptors. Biochem Pharmacol 2012; 84:851-63; PMID:22771828; http://dx.doi.org/10.1016/j.bcp.2012.06.024
   PubMedGoogle Scholar
• Kauferstein S, Kendel Y, Nicke A, Coronas F, Possani L, Favreau P, Križaj I, Wunder C, Kauert G, Mebs D. New conopeptides of the D-superfamily selectively inhibiting neuronal nicotinic acetylcholine receptors. Toxicon: Off J Int Soc Toxinol 2009; 54:295-301; PMID:19393680; http://dx.doi.org/10.1016/j.toxicon.2009.04.016
   PubMedGoogle Scholar
• Whiteaker P, Christensen S, Yoshikami D, Dowell C, Watkins M, Gulyas J, Rivier J, Olivera BM, McIntosh JM. Discovery, synthesis, and structure activity of a highly selective α7 nicotinic acetylcholine receptor antagonist. Biochemistry 2007; 46:6628-38; PMID:17497892; http://dx.doi.org/10.1021/bi7004202
   PubMedGoogle Scholar
• Dutertre S, Ulens C, Büttner R, Fish A, van Elk R, Kendel Y, Hopping G, Alewood PF, Schroeder C, Nicke A. AChBP-targeted α-conotoxin correlates distinct binding orientations with nAChR subtype selectivity. EMBO J 2007; 26:3858-67; PMID:17660751; http://dx.doi.org/10.1038/sj.emboj.7601785
   PubMed Web of Science ®Google Scholar
• Inserra MC, Kompella SN, Vetter I, Brust A, Daly NL, Cuny H, Craik DJ, Alewood PF, Adams DJ, Lewis RJ. Isolation and characterization of α-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors. Biochem Pharmacol 2013; 86:791-9; PMID:23924607; http://dx.doi.org/10.1016/j.bcp.2013.07.016
   PubMed Web of Science ®Google Scholar
• Yu R, Craik DJ, Kaas Q. Blockade of neuronal α7-nAChR by α-conotoxin ImI explained by computational scanning and energy calculations. PLoS Computat Biol 2011; 7:e1002011; PMID:AMBIGUOUS
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Y, An S, Kuang Y, He X, Ma H, Li J, Lv J, Zhang N, Jiang C. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PloS One 2013; 8:e62905;
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29:341-5; PMID:21423189; http://dx.doi.org/10.1038/nbt.1807
   PubMed Web of Science ®Google Scholar
• Hwang do W, Son S, Jang J, Youn H, Lee S, Lee D, Lee YS, Jeong JM, Kim WJ, Lee DS. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011; 32:4968-75; PMID:21489620; http://dx.doi.org/10.1016/j.biomaterials.2011.03.047
   PubMed Web of Science ®Google Scholar
• Fu A, Wang Y, Zhan L, Zhou R. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharmaceut Res 2012; 29:1562-9; PMID:22231987; http://dx.doi.org/10.1007/s11095-012-0667-y
   PubMed Web of Science ®Google Scholar
• Kim JY, Choi WI, Kim YH, Tae G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013; 34:1170-8; PMID:23122677; http://dx.doi.org/10.1016/j.biomaterials.2012.09.047
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan C, Gu B, Meng Q, Wang H, Lu W, Hou H. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target 2011; 19:228-34; PMID:20540685; http://dx.doi.org/10.3109/1061186X.2010.492523
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, Lou J, Jiang C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 2009; 30:4195-202; PMID:19467700; http://dx.doi.org/10.1016/j.biomaterials.2009.02.051
   PubMed Web of Science ®Google Scholar
• Andreu A, Fairweather N, Miller AD. Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. Chembiochem: Eur J Chem Biol 2008; 9:219-31; PMID:18076008; http://dx.doi.org/10.1002/cbic.200700277
   PubMedGoogle Scholar
• Knight A, Carvajal J, Schneider H, Coutelle C, Chamberlain S, Fairweather N. Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin. Eur J Biochem/FEBS 1999; 259:762-9; PMID:10092862
   PubMedGoogle Scholar
• Moreno-Igoa M, Calvo AC, Ciriza J, Munoz MJ, Zaragoza P, Osta R. Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model. Restor Neurol Neurosci 2012; 30:69-80; PMID:22124037
   PubMed Web of Science ®Google Scholar
• Oliveira H, Fernandez R, Pires LR, Martins MC, Simoes S, Barbosa MA, Pego AP. Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J Control Release: Off J Control Release Soc 2010; 143:350-8; PMID:20093157; http://dx.doi.org/10.1016/j.jconrel.2010.01.018
   PubMed Web of Science ®Google Scholar
• Benn SC, Ay I, Bastia E, Chian RJ, Celia SA, Pepinsky RB, Fishman PS, Brown RH, Jr., Francis JW. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. J Neurochem 2005; 95:1118-31; PMID:16271047; http://dx.doi.org/10.1111/j.1471-4159.2005.03459.x
   PubMed Web of Science ®Google Scholar
• Carlton E, Teng Q, Federici T, Yang J, Riley J, Boulis NM. Fusion of the tetanus toxin C fragment binding domain and Bcl-xL for protection of peripheral nerve neurons. Neurosurgery 2008; 63:1175-82; http://dx.doi.org/10.1227/01.NEU.0000334415.45003.EA
   PubMed Web of Science ®Google Scholar
• Francis JW, Hosler BA, Brown RH, Jr., Fishman PS. CuZn superoxide dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells. J Biol Chem 1995; 270:15434-42; PMID:7797532; http://dx.doi.org/10.1074/jbc.270.25.15434
   PubMed Web of Science ®Google Scholar
• Gramlich PA, Remington MP, Amin J, Betenbaugh MJ, Fishman PS. Tat-tetanus toxin fragment C: a novel protein delivery vector and its use with photochemical internalization. J Drug Target 2013; 21:662-74; PMID:23697582; http://dx.doi.org/10.3109/1061186X.2013.796954
   PubMed Web of Science ®Google Scholar
• Larsen KE, Benn SC, Ay I, Chian RJ, Celia SA, Remington MP, Bejarano M, Liu M, Ross J, Carmillo P, et al. A glial cell line-derived neurotrophic factor (GDNF): tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. Brain Res 2006; 1120:1-12; PMID:17020749; http://dx.doi.org/10.1016/j.brainres.2006.08.079
   PubMed Web of Science ®Google Scholar
• Li J, Chian RJ, Ay I, Kashi BB, Celia SA, Tamrazian E, Pepinsky RB, Fishman PS, Brown RH, Jr., Francis JW. Insect GDNF:TTC fusion protein improves delivery of GDNF to mouse CNS. Biochem Biophys Res Commun 2009; 390:947-51; PMID:19852934; http://dx.doi.org/10.1016/j.bbrc.2009.10.083
   PubMed Web of Science ®Google Scholar
• Townsend SA, Evrony GD, Gu FX, Schulz MP, Brown RH, Jr., Langer R. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007; 28:5176-84; PMID:17854886; http://dx.doi.org/10.1016/j.biomaterials.2007.08.011
   PubMed Web of Science ®Google Scholar